Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Dec 25;32(1):6.
doi: 10.3390/curroncol32010006.

A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline-Taxane Chemotherapy in Early HER-2 Negative Breast Cancer

Danilo Giffoni de Mello Morais Mata  1   2   3 , Rossanna C Pezo  4   5 , Kelvin K W Chan  4   5   6 , Ines Menjak  4   5 , Andrea Eisen  7   8 , Maureen Trudeau  4   5
Affiliations
Comparative Study

A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline-Taxane Chemotherapy in Early HER-2 Negative Breast Cancer

Danilo Giffoni de Mello Morais Mata et al. Curr Oncol. .

Abstract

Background: Anthracycline-taxane chemotherapy is the gold standard in high-risk breast cancer (BC), despite the potential risk of congestive heart failure (CHF). A suitable alternative for anthracycline-sparing chemotherapy is through the combination of docetaxel and cyclophosphamide (TC).

Methods: Through a retrospective study of stage I-III HER2-negative BC, using administrative databases, we analyzed a total of 10,634 women treated with adjuvant chemotherapy in Ontario, Canada, between 2009 and 2017. We compared TC versus standardized anthracycline-taxane chemotherapies (ACT and FEC-D). We investigated the overall survival (OS), and explored the incidence of CHF, emergency department (ED) visits and febrile neutropenia.

Results: With a median follow-up of 5.5 years, the 5-year analysis showed an increased OS in patients treated with TC, versus those treated with ACT, HR 0.77 (0.63-0.95, p = 0.015). Among ER+ BC, there was an increased OS in patients treated with ACT and FEC-D, versus those treated with TC, HR 0.70 (0.52-0.95, p = 0.021) and HR 0.71 (0.56-0.91, p = 0.007), respectively. There were no substantial differences in CHF, between TC and anthracycline-based treatments. Patients treated with TC and FEC-D had more ED visits, compared to those treated with ACT.

Conclusion: Our study shows that anthracycline-taxane regimens were the most commonly prescribed adjuvant chemotherapy options in HER2-negative BC. Women who received ACT had the lowest OS, likely due to their unfavorable pathology.

Keywords: adjuvant; doxorubicin; endocrine (hormone) receptor; epirubicin; human epidermal growth factor receptor 2 negative; invasive breast carcinoma; paclitaxel.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Creation of the cohort of breast cancer patients treated with adjuvant chemotherapy.
Figure 2
Figure 2
Kaplan–Meyer estimates of the 5-year overall survival adjusted analysis for women with early HER2-negative breast cancer.
Figure 3
Figure 3
Kaplan–Meyer estimates of the 5-year overall survival adjusted analysis for women with early HER2-negative breast cancer. (A): Endocrine receptor positive populations. (B): Endocrine receptor negative populations.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Female Breast Cancer—Cancer Stat Facts. [(accessed on 18 July 2023)]; Available online: https://seer.cancer.gov/statfacts/html/breast.html.
    1. Cardoso F., Spence D., Mertz S., Corneliussen-James D., Sabelko K., Gralow J., Cardoso M.J., Peccatori F., Paonessa D., Benares A., et al. Global analysis of advanced/metastatic breast cancer: Decade report (2005–2015) Breast. 2018;39:131–138. doi: 10.1016/j.breast.2018.03.002. - DOI - PubMed
    1. Mayer E.L., Fesl C., Hlauschek D., Garcia-Estevez L., Burstein H.J., Zdenkowski N., Wette V., Miller K.D., Balic M., Mayer I.A., et al. Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib with Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03) J. Clin. Oncol. 2022;40:449–458. doi: 10.1200/JCO.21.01918. - DOI - PMC - PubMed
    1. Alferez D.G., Simões B.M., Howell S.J., Clarke R.B. The Role of Steroid Hormones in Breast and Effects on Cancer Stem Cells. Curr. Stem. Cell Rep. 2018;4:81–94. doi: 10.1007/s40778-018-0114-z. - DOI - PMC - PubMed
    1. Yersal O., Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J. Clin. Oncol. 2014;5:412–414. doi: 10.5306/wjco.v5.i3.412. - DOI - PMC - PubMed

Publication types

MeSH terms